Nanomedicine‐Based Immunotherapy for the Treatment of Cancer Metastasis

Metastasis is the leading cause of cancer‐associated death, with poor prognosis even after extensive treatment. The dormancy of metastatic cancer cells during dissemination or after colony formation is one major reason for treatment failure, as most drugs target cells of active proliferation. Immuno...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Advanced materials (Weinheim) Ročník 31; číslo 49; s. e1904156 - n/a
Hlavní autoři: Zhang, Pengcheng, Zhai, Yihui, Cai, Ying, Zhao, Yuliang, Li, Yaping
Médium: Journal Article
Jazyk:angličtina
Vydáno: Germany Wiley Subscription Services, Inc 01.12.2019
Témata:
Animals
Antigen-Presenting Cells - immunology
Cancer
Cancer therapies
Drugs
Humans
Immune system
Immunity, Cellular
Immunotherapy
Immunotherapy - methods
Killer Cells, Natural - immunology
Materials science
Medical prognosis
Metastasis
Nanomaterials
nanomedicine
Nanomedicine - methods
Neoplasm Metastasis - immunology
Neoplasm Metastasis - therapy
Neoplasms - immunology
Neoplasms - therapy
T-Lymphocytes, Cytotoxic - immunology
Tumor Microenvironment
Tumors
nanomedicine
cancer
nanomaterials
metastasis
immunotherapy
ISSN:0935-9648, 1521-4095, 1521-4095
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Metastasis is the leading cause of cancer‐associated death, with poor prognosis even after extensive treatment. The dormancy of metastatic cancer cells during dissemination or after colony formation is one major reason for treatment failure, as most drugs target cells of active proliferation. Immunotherapy has shown great potential in cancer therapy because the activity of effector cells is less affected by the metabolic status of cancer cells. In addition, metastatic cells out of immunosuppressive tumor microenvironment (TME) are more susceptible to immune clearance, although these cells can achieve immune surveillance evasion via strategies such as platelet and macrophage recruitment. Since nanomaterials themselves or their carried drugs have the capability to modulate the immune system, a great amount of focus has been placed on nanomedicine strategies that leverage immune cells participating the metastatic cascade. These nanomedicines successfully inhibit the tumor metastasis and prolong the survival of model animals. Immune cells that are involved in the metastasis cascade are first summarized and then recent and inspiring strategies and nanomaterials in this growing field are highlighted. Recent advances in nanomedicine‐based immunotherapy for the treatment of cancer metastasis are reviewed, starting with a brief introduction of metastasis cascade and nanomedicine‐based cancer immunotherapy. Recent strategies that can modulate key immune cells participating in metastasis cascade including cell intravasation and extravasation, blood circulation, and micrometastatic colony formation and proliferation are summarized.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0935-9648
1521-4095
1521-4095
DOI:10.1002/adma.201904156